Biovie Inc.
BIVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001580149
In the last 90 days, Biovie Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $2.86M in total; no superinvestor holds it.
Other share classesBIVIW
13F holders, Q1 2022
Institutional positions in Biovie Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −1 vs. Q4 2021
- Shares held
- 1.51M
- −141.5K (−8.6%) vs. Q4 2021
- Total value
- $7.14M
- −$311.0K (−4.2%) vs. Q4 2021
- New holders
- 2
- 3 more added
- Sold out
- 3
- 5 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BIVI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $2.86M |
| Q1 2026 | 33 | $1.44M |
| Q4 2025 | 35 | $1.34M |
| Q3 2025 | 32 | $2.28M |
| Q2 2025 | 38 | $1.02M |
| Q1 2025 | 37 | $968.2K |
| Q4 2024 | 43 | $1.52M |
| Q3 2024 | 27 | $195.2K |
| Q2 2024 | 50 | $1.79M |
| Q1 2024 | 51 | $3.55M |
| Q4 2023 | 54 | $2.32M |
| Q3 2023 | 57 | $5.95M |
| Q2 2023 | 53 | $8.29M |
| Q1 2023 | 48 | $13.0M |
| Q4 2022 | 39 | $9.50M |
| Q3 2022 | 18 | $1.20M |
| Q2 2022 | 16 | $1.60M |
| Q1 2022 | 14 | $7.14M |
| Q4 2021 | 15 | $7.45M |
| Q3 2021 | 14 | $9.96M |
| Q2 2021 | 12 | $4.85M |
| Q1 2021 | 13 | $4.62M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Biovie Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 837 | $4.00K | 0.00% | +837 | New |
| Advisor Group Holdings, Inc. | 1,000 | $5.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,500 | $7.00K | 0.00% | −2−0.1% | Reduced |
| UBS Group AG | 2,109 | $10.0K | 0.00% | −12−0.6% | Reduced |
| Bank of America Corp | 2,200 | $10.0K | 0.00% | +2,200 | New |
| Wells Fargo & Company | 2,681 | $13.0K | 0.00% | +2,651+8,836.7% | Added |
| BlackRock Inc. | 9,547 | $45.0K | 0.00% | −477−4.8% | Reduced |
| State Street Corp | 15,112 | $71.0K | 0.00% | +312+2.1% | Added |
| Long Focus Capital Management, LLC | 20,000 | $94.0K | 0.02% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 34,387 | $162.0K | 0.00% | +6,019+21.2% | Added |
| swisspartners Ltd. | 80,521 | $380.0K | 0.30% | 00.0% | Unchanged |
| Vanguard Group Inc | 164,480 | $776.0K | 0.00% | 00.0% | Unchanged |
| Kepos Capital LP | 565,000 | $2.67M | 0.20% | −60,000−9.6% | Reduced |
| Sabby Management, LLC | 612,914 | $2.89M | 1.24% | −35,331−5.5% | Reduced |
| Royal Bank of Canada | 0 | $0 | 0.00% | −23,500−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −23,565−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,600−100.0% | Sold out |